StockData

Ligand Pharmaceuticals vs Maravai LifeSciences

LGND and MRVI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGND and MRVI compare

Ligand Pharmaceuticals is the larger company, worth 3.1 times as much as Maravai LifeSciences ($6.0B against $1.9B).

Ligand Pharmaceuticals grew revenue faster over the last twelve months (1.0% versus −5.0% for Maravai LifeSciences).

Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −37.1% at Maravai LifeSciences.

Maravai LifeSciences scores higher on the StockData Score (7 against 6 for Ligand Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGNDMRVI
Size and price
Market cap$6.0B$1.9B
Share price$301.71$7.40
Change, 1 year49.9%128%
Change, 5 years92.4%−82.2%
Beta (5Y)0.800.29
Employees47435
StockData Score
Total score67 (better)
Valuation score00
Growth score12 (better)
Performance score3 (better)2
Health score23 (better)
Dividend score00
Valuation
P/E132×–
P/S23.8×9.2× (better)
P/B6.3× (better)9.4×
EV/EBITDA111×–
P/FCF66.6×–
FCF yield1.5% (better)−1.9%
Fair value$55.27$2.74
Margin of safety−446%−170% (better)
Growth
Revenue growth (TTM)1.0% (better)−5.0%
Revenue growth, 5Y average10.4% (better)−8.1%
Net income growth (TTM)5.9%–
EPS growth (TTM)18.7%–
Profitability
Gross margin–34.9%
Operating margin10.1% (better)−56.1%
Net margin20.3% (better)−37.1%
FCF margin35.7% (better)−17.2%
Return on equity5.4% (better)−32.9%
Return on invested capital2.6% (better)−32.4%
Financial health
Debt / equity1.170.72 (better)
Net debt / EBITDA11.26–
Interest coverage3.1× (better)−4.9×
Current ratio1.224.05 (better)
Altman Z-score3.394.57 (better)
Piotroski F-score6 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions113%55.5%
Held by insiders2.6%3.6%
Insider net buying, 12 months−$35.7M$115K (better)
Short interest, % of float–5.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.